Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA

Aortic Valve Stenosis Clinical Trial

— RADIANT CANADA  

Official title:

Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02838680
• Other study ID #: HLT1502
• Status: Completed
• Phase: N/A
• Start date: December 2016
• Est. completion date: October 31, 2022

Study information

• Verified date: May 2023
• Source: HLT Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and performance of the HLT System in patients with severe aortic stenosis who present at high risk for aortic valve replacement surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 31, 2022
• Est. primary completion date: April 9, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

1. 70 years of age or older

2. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 , mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec

3. Symptomatology due to aortic stenosis resulting in one of the following:

1. NYHA Functional Classification of II or greater

2. Presence of angina

3. Presence of syncope

4. Aortic valve annular diameter = 24 and =26 mm measured by MSCT based on area or perimeter

5. STS score of =8, or documented heart team agreement of high risk for surgical aortic valve replacement (SAVR) due to frailty or comorbidities.

6. Geographically available, willing to comply with follow up and able to provide written informed consent

Exclusion Criteria:

1. Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success.

2. Patients at high risk for coronary obstruction in the opinion of the investigator (e.g. combination of a coronary height < 12 mm and coronary sinus diameter < 30 mm)

3. Patients with low flow/low gradient aortic stenosis

4. Patients with significant annular calcification (e.g. Agatston score > 4000)

5. Pre-existing prosthetic heart valve in any position, or prosthetic ring

6. Severe aortic, mitral or tricuspid valve regurgitation

7. Moderate to severe mitral stenosis

8. Myocardial infarction within the past 30 days*

9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation

10. LVEF < 30%

11. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure

12. Hemodynamic instability requiring inotropic drug therapy within the past 14 days

13. Untreated clinically significant coronary artery disease requiring revascularization

14. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery

15. Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy

16. Patient ineligible for or refuses blood transfusions

17. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or vessels < 6 mm) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT

18. Active peptic ulcer or gastrointestinal bleeding within the past 90 days*

19. Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 month, or treatment of carotid stenosis within past two months*

20. Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease requiring chronic dialysis

21. Active infection requiring ongoing treatment

22. Need for emergent surgery or intervention other than the investigational procedure

23. Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure except for PCI which is within 7 days of the index procedure*

24. Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated

25. Life expectancy < 1 year due to non-cardiac co-morbid conditions

26. Currently participating in any investigational drug or device studies that may confound the results of this study

27. History of any cognitive or mental health status that would interfere with study participation * At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility.

Related Conditions & MeSH terms

• Aortic Valve Stenosis

Intervention

Device:
• HLT Transcatheter Aortic Valve System
Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System

Locations

Country	Name	City	State
Canada	Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval	Québec City	Quebec
Canada	Sunnybrook Health Sciences Center	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
HLT Inc.

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Rodes-Cabau J, Williams MR, Wijeysundera HC, Kereiakes DJ, Paradis JM, Staniloae C, Saric M, Radhakrishnan S, Wilson RF, Kubo SH. Transcatheter Aortic Valve Replacement With the HLT Meridian Valve. Circ Cardiovasc Interv. 2019 Aug;12(8):e008053. doi: 10.1 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoint: Mortality at 30 days	The primary safety endpoint is all-cause mortality at 30 days	30 days
Secondary	Secondary Performance Endpoint 1: Procedural Device Performance	The secondary performance endpoint is Device Success defined as: Absence of procedural mortality AND; Correct positioning of a single Valve into the proper anatomical location AND; Intended performance of the Valve (no severe prosthesis-patient mismatch and clinically acceptable gradient) AND no moderate or severe aortic valve regurgitation)	1 day
Secondary	Secondary Performance Endpoint 2: Post-procedural Valve Performance (Aortic Valve Effective Orifice Area)	Aortic valve effective orifice area (EOA) will be evaluated with echocardiograms	1 week, 1, 6, 12, 24, 36, 48 and 60 months
Secondary	Secondary Performance Endpoint 2: Post-procedural Valve Performance (Severity of Aortic Valve Regurgitation)	Severity of aortic valve regurgitation (AR) will be evaluated with echocardiograms	1 week, 1, 6, 12, 24, 36, 48 and 60 months
Secondary	Secondary Performance Endpoint 2: Post-procedural Valve Performance (Aortic Valve Gradient)	Aortic valve gradient will be evaluated with echocardiograms	1 week, 1, 6, 12, 24, 36, 48 and 60 months
Secondary	Secondary Safety Endpoint 3: Adverse Events	All adverse events will be assessed throughout the 5 year follow up period.	throughout the 5 year follow up period